nach oben

Archives of Dermatological Research

Erschienen in:

02.12.2022 | REVIEW

Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges

verfasst von: Maria Karim, Robert S. Boikess, Robert A. Schwartz, Philip J. Cohen

Erschienen in: Archives of Dermatological Research | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Dimethyl sulfoxide (DMSO) is a clear, odorless liquid, inexpensively produced as a by-product of the wood pulp industry. DMSO’s unique chemical properties allow for its broad applications in a wide variety of cutaneous challenges. Widely available in the USA as a solvent, DMSO is FDA-approved only for the treatment of interstitial cystitis and for use as a preservative for organ transplant. DMSO readily penetrates and diffuses through biological membranes. At low concentrations, DMSO exhibits anti-inflammatory, analgesic, diuretic, vasodilator, anti-platelet aggregation, radio-protective, and muscle-relaxing properties. DMSO is also a vigorous scavenger of hydroxyl free radicals, which may explain its observed beneficial effects on skin rejuvenation and recovery from thermal injury. DMSO has a relatively low level of toxicity. DMSO has shown promise in the off-label treatment of basal cell carcinoma, pressure ulcers, scleroderma, herpes simplex, cutaneous fungal infections, and amyloidosis. The potential of DMSO to serve as an independent or adjuvant topical treatment for these conditions is explored in this review.

Boikess RS (2015) Chemical principles for organic chemistry, 1st edn. CT: Cengage Learning, Stamford, pp 28–29

Young VL, Boswell CB, Centeno RF, Watson ME (2005) DMSO: applications in plastic surgery. Aesthet Surg J 25(2):201–209PubMedCrossRef

Wu X-F, Natte K (2016) The applications of dimethyl sulfoxide as reagent in organic synthesis. Adv Synth Catal 358(3):336–352CrossRef

Gavrilin MV, Sen’chukova GV, Kompantseva EV (2000) Structure of chemical compounds, methods of analysis and process control for the synthesis and analysis of dimethyl sulfoxide. Pharm Chem J 34(9):490CrossRef

Szmant HH (1975) Physical properties of dimethyl sulfoxide and its function in biological systems. Ann N Y Acad Sci 243:20–23PubMedCrossRef

Kharasch N, Thyagarajan BS (1983) Structural basis for biological activities of dimethyl sulfoxide. Ann N Y Acad Sci 411:391–402PubMedCrossRef

Verheijen M, Lienhard M, Schrooders Y et al (2019) DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. Sci Rep 9(1):4641PubMedPubMedCentralCrossRef

Pielesz A, Gawłowski A, Biniaś D et al (2018) The role of dimethyl sulfoxide (DMSO) in ex-vivo examination of human skin burn injury treatment. Spectrochim Acta A Mol Biomol Spectrosc 196:344–352PubMedCrossRef

Kollerup Madsen B, Hilscher M, Zetner D, Rosenberg J (2018) Adverse reactions of dimethyl sulfoxide in humans: a systematic review. F1000Res 7:1746PubMedCrossRef

10.

Notman R, Noro M, O’Malley B, Anwar J (2006) Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. J Am Chem Soc 128(43):13982–13983PubMedCrossRef

11.

Nada AH, Zaghloul AA, Hedaya MM, Khattab IS (2014) Development of novel formulations to enhance in vivo transdermal permeation of tocopherol. Acta Pharm 64(3):299–309PubMedCrossRef

12.

Wood DC, Wood J (1975) Pharmacologic and biochemical considerations of dimethyl sulfoxide. Ann N Y Acad Sci 243:7–19PubMedCrossRef

13.

Maibach HI, Feldmann RJ (1967) The effect of DMSO on percutaneous penetration of hydrocortisone and testosterone in man. Ann N Y Acad Sci 141(1):423–427PubMedCrossRef

14.

Jacob SW, Wood DC (1967) Dimethyl sulfoxide (DMSO). Toxicology, pharmacology, and clinical experience. Am J Surg 114(3):414–426PubMedCrossRef

15.

Ashwood-Smith MJ (1975) Current concepts concerning radioprotective and cryoprotective properties of dimethyl sulfoxide in cellular systems. Ann N Y Acad Sci 243:246–256PubMedCrossRef

16.

Del Maestro R, Thaw HH, Björk J, Planker M, Arfors KE (1980) Free radicals as mediators of tissue injury. Acta Physiol Scand Suppl 492:43–57PubMed

17.

Panganamala RV, Sharma HM, Heikkila RE, Geer JC, Cornwell DG (1976) Role of hydroxyl radical scavengers dimethyl sulfoxide, alcohols and methional in the inhibition of prostaglandin biosynthesis. Prostaglandins 11(4):599–607PubMedCrossRef

18.

Haigler HJ, Spring DD (1983) Comparison of the analgesic effects of dimethyl sulfoxide and morphine. Ann N Y Acad Sci 411:19–27PubMedCrossRef

19.

Görög P, Kovács IB (1968) Effect of dimethyl sulfoxide (DMSO) on various experimental inflammations. Curr Ther Res Clin Exp 10(9):486–492PubMed

20.

Ang JM, Riaz IB, Kamal MU, Paragh G, Zeitouni NC (2017) Photodynamic therapy and pain: a systematic review. Photodiagnosis Photodyn Ther 19:308–344PubMedCrossRef

21.

Peng Q, Warloe T, Moan J et al (1995) Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 62(5):906–913PubMedCrossRef

22.

Warloe T, Peng Q, Heyerdahl H et al (1995) Photodynamic therapy with 5-aminolevulinic acid induced porphyrins and DMSO/EDTA for basal cell carcinoma. 5th International Photodynamic Association Biennial Meeting. SPIE 2371: 226–235

23.

Soler AM, Warloe T, Tausjø J, Berner A (1999) Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 79(3):204–206PubMedCrossRef

24.

Moore ZE, Webster J (2018) Dressings and topical agents for preventing pressure ulcers. Cochrane Database Syst Rev 12(12):CD009362PubMed

25.

Lishner M, Lang R, Kedar I, Ravid M (1985) Treatment of diabetic perforating ulcers (mal perforant) with local dimethylsulfoxide. J Am Geriatr Soc 33(1):41–43PubMedCrossRef

26.

Duimel-Peeters IGP, Halfens RJ, Snoeckx LH et al (2003) A systematic review of the efficacy of topical skin application of dimethyl sulfoxide on wound healing and as an anti-inflammatory drug. Wounds 15(11):361–370

27.

Ting WW, Sontheimer RD (2001) Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus 10(3):171–184PubMedCrossRef

28.

Gries G, Bublitz G, Lindner J (1967) The effect of dimethyl sulfoxide on the components of connective tissue. (Clinical and experimental investigations). Ann N Y Acad Sci 141(1):630–637PubMedCrossRef

29.

Frommhold W, Bublitz G, Gries G (1967) The use of DMSO for the treatment of postirradiation subcutaneous plaques. Ann N Y Acad Sci 141(1):603–612PubMedCrossRef

30.

Scherbel AL, McCormack LJ, Layle JK (1967) Further observations on the effect of dimethyl sulfoxide in patients with generalized scleroderma. (Progressive systemic sclerosis). Ann N Y Acad Sci 141(1):613–629PubMedCrossRef

31.

Engel MF (1972) Dimethyl sulfoxide in the treatment of scleroderma. South Med J 65(1):71–73PubMedCrossRef

32.

Scherbel AL (1983) The effect of percutaneous dimethyl sulfoxide on cutaneous manifestations of systemic sclerosis. Ann N Y Acad Sci 411:120–130PubMedCrossRef

33.

Binnick SA, Shore SS, Corman A, Fleischmajer R (1977) Failure of dimethyl sulfoxide in the treatment of scleroderma. Arch Dermatol 113(10):1398–1402PubMedCrossRef

34.

Williams HJ, Furst DE, Dahl SL et al (1985) Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 28(3):308–314PubMedCrossRef

35.

Fatahzadeh M, Schwartz RA (2007) Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 57(5):737–766PubMedCrossRef

36.

Dawber R (1974) Idoxuridine in herpes zoster: further evaluation of intermittent topical therapy. Br Med J 2(5918):526–527PubMedPubMedCentralCrossRef

37.

Spruance SL, McKeough MB, Cardinal JR (1983) Dimethyl sulfoxide as a vehicle for topical antiviral chemotherapy. Ann N Y Acad Sci 411:28–33PubMedCrossRef

38.

Aguilar JS, Roy D, Ghazal P, Wagner EK (2002) Dimethyl sulfoxide blocks herpes simplex virus-1 productive infection in vitro acting at different stages with positive cooperativity. Application of micro-array analysis. BMC Infect Dis. https://doi.org/10.1186/1471-2334-2-9CrossRefPubMedPubMedCentral

39.

Randhawa MA (2006) The effect of dimethyl sulfoxide (DMSO) on the growth of dermatophytes. Nippon Ishinkin Gakkai Zasshi 47(4):313–318CrossRef

40.

Kligman AM (1965) Topical pharmacology and toxicology of dimethyl sulfoxide—part 1. JAMA 193:796–804PubMedCrossRef

41.

Leeyaphan C, Suiwongsa B, Komesmuneeborirak P et al (2021) Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: a pilot study [published online ahead of print, 2021 Oct 26]. Indian J Dermatol Venereol Leprol. https://doi.org/10.25259/IJDVL_359_2021CrossRef

42.

Weidner T, Illing T, Elsner P (2017) Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol 18(5):629–642PubMedCrossRef

43.

Ozkaya-Bayazit E, Kavak A, Güngör H, Ozarmagan G (1998) Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol 37(12):949–954PubMedCrossRef

44.

Mansoor M, Kapadia N, Talat H et al (2017) Lichen amyloidosis: evaluation of the efficacy of topical dimethyl sulfoxide (DMSO) 70% in Abbasi Shaheed hospital. Karachi Professional Med J 24(7):1020–1026

45.

Saki N, Ahramiyanpour N, Heiran A, Alipour S, Parvizi MM (2020) Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: a split-side single-blinded randomized clinical trial. Dermatol Ther 33(3):13305–8. https://doi.org/10.1111/dth.13305CrossRef

Titel: Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges
verfasst von: Maria Karim
Robert S. Boikess
Robert A. Schwartz
Philip J. Cohen
Publikationsdatum: 02.12.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 6/2023
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-022-02494-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Psoriasis associated with asthma and allergic rhinitis: a US-based cross-sectional study using the All of US Research Program

Importance of a multi-tiered treatment approach for intellectually and developmentally disabled patients with hidradenitis suppurativa

The relationship of quality of life and acne severity with chronotype and insomnia in patients with acne vulgaris

Ethnoracial representation in hidradenitis suppurativa clinical trials

Potential treatment modalities for suprapubic adiposity and pubic contouring